McKesson Corporation vs Skyworks Solutions Inc — how do they compare? McKesson Corporation trades at $940.9 (market cap $108.46B), while Skyworks Solutions Inc trades at $77.52 (market cap $12.15B). The key difference: McKesson Corporation is far larger — about 8.9× Skyworks Solutions Inc's market cap, and Skyworks Solutions Inc pays the higher dividend (4.13%). Which is the better fit depends on your goals — on Pluang, investors hold McKesson Corporation for 74 Days and Skyworks Solutions Inc for 50 Days on average.
| MCK | SWKS | |
|---|---|---|
Market Cap | $108.46B | $12.15B |
Volume | 712,607 | 7,390,810 |
Sector | Health | Technology |
52-Week High | $995.69 | $91.45 |
52-Week Low | $725.17 | $52.50 |
Typical Hold Time | 74 Days | 50 Days |
Enterprise Value | $115.00B | $12.03B |
Dividend Yield | 0.4% | 4.13% |
Signals from Pluang's Aura AI — not financial advice
McKesson Corporation (MCK) trades at $937.98, up 3.04% with strong technical momentum and bullish analyst sentiment. The stock shows consistent earnings beats with Q2 2026 EPS of $9.93 exceeding expectations of $9.56. Recent positive developments include the CVS Health partnership extension through 2032 and raised full-year guidance. Revenue growth remains robust at $359.05 billion for 2025, though net margins are thin at 1.12%.
The outlook remains positive with 81% analyst buy ratings and a $956.43 consensus target. Key risks include margin pressure from drug pricing dynamics and policy uncertainty. Strong cash flow generation ($6.09B operating cash flow) supports the dividend and growth initiatives, while technical indicators show the stock testing resistance near $938.
Skyworks Solutions (SWKS) trades at $77.17, down 7.5% in the last session, with a bearish technical signal. The stock has beaten earnings estimates for the last three quarters, but revenue and net income have declined year-over-year. The pending merger with Qorvo is a key development, with regulatory clearances obtained, targeting $500 million in synergies. Analyst consensus is a Buy with a $78.80 price target, slightly above the current price.
The outlook is mixed: the Qorvo merger offers growth potential and cost savings, but declining profitability and negative cash flow pose risks. Investor sentiment is cautious due to recent price volatility and earnings pressure. Upside depends on merger execution and market recovery, while downside risks include integration challenges and competitive pressures.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
McKesson is a leading wholesaler of branded, generic, and specialty pharmaceutical products to pharmacies (retail chains, independent, and mail order), hospitals networks, and healthcare providers. Along with AmerisourceBergen and Cardinal Health, the three account for well over 90% of the U.S. pharmaceutical wholesale industry. McKesson is currently divesting from its pharmaceutical wholesale and distribution in Europe and Canada in order to redeploy capital to strategic growth areas in the U.S. (oncology network and ecosystem, and biopharma services). Additionally, the company supplies medical-surgical products and equipment to healthcare facilities and provides a variety of technology solutions for pharmacies.
Read more on MCK →Skyworks Solutions produces semiconductors for wireless handsets and other devices that are used to enable wireless connectivity. Its main products include power amplifiers, filters, switches, and integrated front-end modules that support wireless transmissions. Skyworks' customers are mostly large smartphone manufacturers, but the firm also has a growing presence in nonhandset applications such as wireless routers, medical devices, and automobiles.
Read more on SWKS →